Cargando…
Mitochondrial dysfunction in fibrotic diseases
Although fibrosis is a common pathological feature of most end-stage organ diseases, its pathogenesis remains unclear. There is growing evidence that mitochondrial dysfunction contributes to the development and progression of fibrosis. The heart, liver, kidney and lung are highly oxygen-consuming or...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7474731/ https://www.ncbi.nlm.nih.gov/pubmed/32963808 http://dx.doi.org/10.1038/s41420-020-00316-9 |
_version_ | 1783579374978596864 |
---|---|
author | Li, Xinyu Zhang, Wei Cao, Qingtai Wang, Zeyu Zhao, Mingyi Xu, Linyong Zhuang, Quan |
author_facet | Li, Xinyu Zhang, Wei Cao, Qingtai Wang, Zeyu Zhao, Mingyi Xu, Linyong Zhuang, Quan |
author_sort | Li, Xinyu |
collection | PubMed |
description | Although fibrosis is a common pathological feature of most end-stage organ diseases, its pathogenesis remains unclear. There is growing evidence that mitochondrial dysfunction contributes to the development and progression of fibrosis. The heart, liver, kidney and lung are highly oxygen-consuming organs that are sensitive to mitochondrial dysfunction. Moreover, the fibrotic process of skin and islet is closely related to mitochondrial dysfunction as well. This review summarized emerging mechanisms related to mitochondrial dysfunction in different fibrotic organs and tissues above. First, it highlighted the important elucidation of mitochondria morphological changes, mitochondrial membrane potential and structural damage, mitochondrial DNA (mtDNA) damage and reactive oxidative species (ROS) production, etc. Second, it introduced the abnormality of mitophagy and mitochondrial transfer also contributed to the fibrotic process. Therefore, with gaining the increasing knowledge of mitochondrial structure, function, and origin, we could kindle a new era for the diagnostic and therapeutic strategies of many fibrotic diseases based on mitochondrial dysfunction. |
format | Online Article Text |
id | pubmed-7474731 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-74747312020-09-21 Mitochondrial dysfunction in fibrotic diseases Li, Xinyu Zhang, Wei Cao, Qingtai Wang, Zeyu Zhao, Mingyi Xu, Linyong Zhuang, Quan Cell Death Discov Review Article Although fibrosis is a common pathological feature of most end-stage organ diseases, its pathogenesis remains unclear. There is growing evidence that mitochondrial dysfunction contributes to the development and progression of fibrosis. The heart, liver, kidney and lung are highly oxygen-consuming organs that are sensitive to mitochondrial dysfunction. Moreover, the fibrotic process of skin and islet is closely related to mitochondrial dysfunction as well. This review summarized emerging mechanisms related to mitochondrial dysfunction in different fibrotic organs and tissues above. First, it highlighted the important elucidation of mitochondria morphological changes, mitochondrial membrane potential and structural damage, mitochondrial DNA (mtDNA) damage and reactive oxidative species (ROS) production, etc. Second, it introduced the abnormality of mitophagy and mitochondrial transfer also contributed to the fibrotic process. Therefore, with gaining the increasing knowledge of mitochondrial structure, function, and origin, we could kindle a new era for the diagnostic and therapeutic strategies of many fibrotic diseases based on mitochondrial dysfunction. Nature Publishing Group UK 2020-09-05 /pmc/articles/PMC7474731/ /pubmed/32963808 http://dx.doi.org/10.1038/s41420-020-00316-9 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Review Article Li, Xinyu Zhang, Wei Cao, Qingtai Wang, Zeyu Zhao, Mingyi Xu, Linyong Zhuang, Quan Mitochondrial dysfunction in fibrotic diseases |
title | Mitochondrial dysfunction in fibrotic diseases |
title_full | Mitochondrial dysfunction in fibrotic diseases |
title_fullStr | Mitochondrial dysfunction in fibrotic diseases |
title_full_unstemmed | Mitochondrial dysfunction in fibrotic diseases |
title_short | Mitochondrial dysfunction in fibrotic diseases |
title_sort | mitochondrial dysfunction in fibrotic diseases |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7474731/ https://www.ncbi.nlm.nih.gov/pubmed/32963808 http://dx.doi.org/10.1038/s41420-020-00316-9 |
work_keys_str_mv | AT lixinyu mitochondrialdysfunctioninfibroticdiseases AT zhangwei mitochondrialdysfunctioninfibroticdiseases AT caoqingtai mitochondrialdysfunctioninfibroticdiseases AT wangzeyu mitochondrialdysfunctioninfibroticdiseases AT zhaomingyi mitochondrialdysfunctioninfibroticdiseases AT xulinyong mitochondrialdysfunctioninfibroticdiseases AT zhuangquan mitochondrialdysfunctioninfibroticdiseases |